Talazoparib poly ADP-ribose polymerase (PARP) inhibitor

BMN 673



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - poly ADP-ribose polymerase (PARP) inhibitor in all type of patients - poly ADP-ribose polymerase (PARP) inhibitor in BRCA-mutated

EMBRACA ongoing talazoparibPhysician s choice chemotherapyNA NCT01945775



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons